340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.

antineoplastic agents health policy oncology nursing outpatient clinics

Journal

Clinical journal of oncology nursing
ISSN: 1538-067X
Titre abrégé: Clin J Oncol Nurs
Pays: United States
ID NLM: 9705336

Informations de publication

Date de publication:
01 04 2019
Historique:
entrez: 19 3 2019
pubmed: 19 3 2019
medline: 6 5 2020
Statut: ppublish

Résumé

The 340B Drug Pricing Program is a complex federal program that is intended to provide financial relief to hospitals that provide care to greater volumes of low-income, uninsured, and underinsured patients. The body of literature is growing on how cancer care has transformed since freestanding cancer hospitals became eligible for the 340B program. Currently, community oncology practices are not eligible for the 340B program.

Identifiants

pubmed: 30880808
doi: 10.1188/19.CJON.217-219
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Pagination

217-219

Auteurs

Alex Fauer (A)

University of Michigan School of Nursing and University of Michigan Rogel Cancer Center.

Christopher R Friese (CR)

University of Michigan School of Nursing and University of Michigan Rogel Cancer Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH